NCT03313687 SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK
| NCT ID | NCT03313687 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitätsklinikum Hamburg-Eppendorf |
| Condition | Cardiogenic Shock |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,500 participants |
| Start Date | 2017-09-01 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,500 participants in total. It began in 2017-09-01 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
International, observational registry to investigate the outcome in patients with cardiogenic shock. The primary aim of this study is to investigate the clinical outcome of patients in cardiogenic shock.
Eligibility Criteria
Inclusion Criteria: * Patients with cardiogenic shock treated at a tertiary care hospital. Exclusion Criteria: * Age ≤17 years.
Contact & Investigator
Dirk Westermann, MD
PRINCIPAL INVESTIGATOR
UHZ
Frequently Asked Questions
Who can join the NCT03313687 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiogenic Shock. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03313687 currently recruiting?
Yes, NCT03313687 is actively recruiting participants. Contact the research team at b.schrage@uke.de for enrollment information.
Where is the NCT03313687 trial being conducted?
This trial is being conducted at Hamburg, Germany.
Who is sponsoring the NCT03313687 clinical trial?
NCT03313687 is sponsored by Universitätsklinikum Hamburg-Eppendorf. The principal investigator is Dirk Westermann, MD at UHZ. The trial plans to enroll 2,500 participants.